Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 46

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 46
---
— — — (143,466)— (143,466)Balance at September 30, 202446,985 (837)$47 $(25,121)$996,376 $(222,397)$678 $749,583 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  5

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(In thousands)

(Unaudited)

 Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome  Common SharesTreasury SharesCommon StockTreasury StockTotalBalance at December 31, 202447,078 (837)$47 $(25,121)$1,009,435 $(206,356)$343 $778,348 Exercise of stock options1 — — — 12 — — 12 Vested restricted stock units765 — 1 — — — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units(210)— — — (5,474)— — (5,474)Common stock issued under employee stockpurchase plan101 — — — 1,569 — — 1,569 Stock-based compensation— — — — 44,003 — — 44,003 Purchase of treasury stock, inclusive of excise tax and broker fees— (3,932)— (100,422)— — — (100,422)Other comprehensive income (Note 11)— — — — — — 3,780 3,780 Net income— — — — — 5,397 — 5,397 Balance at September 30, 202547,735 (4,769)$48 $(125,543)$1,049,545 $(200,959)$4,123 $727,214  

Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncomeCommon SharesTreasury SharesCommon StockTreasury StockTotalBalance at